
    
      This is a phase I study of eribulin, a novel tubulin inhibitor in children with relapsed and
      refractory solid tumors including lymphoma. Dose escalation will be performed in a classic
      3+3 design starting with 75% of the adult maximum tolerated dose (MTD). Pharmacokinetics will
      be done on each patient. Primary endpoint will be the pediatric MTD.
    
  